cFMS Receptor Inhibitor II is a cFMS inhibitor.

BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM and > 3200-fold higher than its affinity for other kinases.

Ki-20227 is a highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50 value of 2 nM, displaying 6 fold and > 100 fold selectivity over VEGFR2 (IC50=12 nM) and c-Kit/PDGFRβ (IC50=451/217 nM), respectively.

Pazopanib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.

GW2580 is a selective CSF-1R inhibitor for c-FMS with IC50 of 30 nM, 150- to 500-fold selective compared to b-Raf, CDK4, c-KIT, c-SRC, EGFR, ERBB2/4, ERK2, FLT-3, GSK3, ITK, JAK2 etc.

Pexidartinib is a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with IC50s of 20, 10, and 160 nM in vitro, respectively.

PRN1371 is an irreversible covalent FGFR inhibitor used for the treatment of solid tumor.

AZ304 is an inhibitor of BRAF and can target many kinases. The IC50s for wild type BRAF, V600E mutant BRAF and wild type CRAF are 79 nM, 38 nM and 68 nM, respectively. It can also inhibit p38 (IC50 = 6 nM) and CSF1R (IC50 = 35 nM).

OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively and also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.

PLX5622 is a highly selective brain-penetrant CSF1R inhibitor allowing for extended and specific microglial elimination, preceding and during pathology development.

JNJ-40346527 is an orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R) with potential antineoplastic activity.